LL-37

LL-37 (Human Cathelicidin Peptide) is an endogenous human cathelicidin peptide with dual antimicrobial and immunomodulatory properties. It combats pathogens while enhancing wound healing and tissue regeneration.

Wound Healing: Faster healing of chronic ulcers; marked decrease in wound area; enhanced granulation tissue formation
Diabetic Foot Ulcers: Improved wound closure and tissue regeneration
Antimicrobial Activity: Direct activity against Gram(+) and Gram(-) pathogens; reduces infection persistence
Anti-Inflammatory: Dampens excessive inflammation at wound sites
Angiogenesis & Tissue Repair: Stimulates new blood vessel formation, keratinocyte migration, and proliferation
Refractory Wounds: Effective in large wounds (≥10 cm²) and hard-to-heal venous leg ulcers
Safety Profile: Well-tolerated, no significant adverse effects at therapeutic doses

Grönberg, A., et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair and Regeneration, 22(5), 613–621. DOI
Mahlapuu, M., et al. (2021). Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair and Regeneration, 29(6), 938–950. DOI
Miranda, E., et al. (2023). Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Archives of Dermatological Research, 315, 2623–2633. DOI
Duplantier, A.J., & van Hoek, M.L. (2013). The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. Frontiers in Immunology, 4, 143. DOI
Yang, X., et al. (2020). Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model. Military Medical Research, 7, 20. DOI

$99.00

Per Unit

In stock